Widespread appreciation of the complexity of signaling pathways involving the protein tyrosine kinase (PTK) superfamily of enzymes has resulted in the need for more sophisticated reagents to dissect the role of PTKs in normal and disease states. To meet this need, Promega has developed the SignaTECT™ PTK Assay System, a novel method based on the use of optimized PTK Biotinylated Peptide Substrates in conjunction with the unique SAM2™ Biotin Capture Membrane. This system provides selective, accurate and rapid detection of PTK activity, while minimizing handling and radioisotope requirements. The SignaTECT™ PTK Assay System is a broad-specificity assay that measures the activity of a wide variety of PTKs, including both transmembrane receptor and cytosolic enzymes.
Promega Notes 59, 2.
Erik Schaefer1, Kevin Hsaio1 and 2Scott Guimond
1Promega Corporation. 2Department of Pathology, University of Wisconsin.